Cargando…

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature

We present the case of a 53-year-old male with metastatic rectal cancer who was treatment resistant to FOLFOX and FOLFOXIRI. Due to a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, regorafenib was given in the third line setting. Surprisingly, the patient had a prolonged partial respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korphaisarn, Krittiya, Loree, Jonathan M., Nguyen, Van, Coulson, Ryanne, Holla, Vijaykumar, Litzenburger, Beate C., Chen, Ken, Mills, Gordon B., Maru, Dipen M., Meric-Bernstan, Funda, Shaw, Kenna R. Mills, Kopetz, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593691/ https://www.ncbi.nlm.nih.gov/pubmed/28915719 http://dx.doi.org/10.18632/oncotarget.18357

Ejemplares similares

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers
por: Kopetz, Scott, et al.
Publicado: (2019)

Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2019)

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature
por: Khan, Maliha, et al.
Publicado: (2017)

ALK: a tyrosine kinase target for cancer therapy
por: Holla, Vijaykumar R., et al.
Publicado: (2017)

Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients
por: Luangdilok, Sutima, et al.
Publicado: (2014)

Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review
por: Archwamety, Anita, et al.
Publicado: (2022)

Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature
por: Chen, Guocai, et al.
Publicado: (2015)

KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2016)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

Anorectal avulsion: an exceptional rectal trauma
por: Ibn majdoub Hassani, Karim, et al.
Publicado: (2013)

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
por: Raghav, Kanwal, et al.
Publicado: (2016)

Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy
por: Zeng, Jia, et al.
Publicado: (2014)

Low Fat-Free Mass Index Measured by Bioelectrical Impedance Analysis Correlates With Hematologic Adverse Events in Early-Stage Breast Cancer Patients Receiving Chemotherapy: A Prospective Observational Cohort Study
por: Thanestada, Jirawat, et al.
Publicado: (2022)

Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer
por: Chowdhury, Saikat, et al.
Publicado: (2021)

Actionability classification of variants of unknown significance correlates with functional effect
por: Johnson, Amber, et al.
Publicado: (2023)

Molecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative Setting
por: Coulson, Ryanne
Publicado: (2015)

Comparative molecular characterization of typical and exceptional responders in glioblastoma
por: Wipfler, Kristin, et al.
Publicado: (2018)

Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer
por: Raissouni, Soundouss, et al.
Publicado: (2015)

Comparison of guidelines on rectal cancer: exception proves the rule?
por: Dou, Ruoxu, et al.
Publicado: (2021)

Recent developments in the treatment of metastatic colorectal cancer
por: Loree, Jonathan M., et al.
Publicado: (2017)

Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B
por: Potts, Malia B., et al.
Publicado: (2015)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab
por: Madabhavi, Irappa, et al.
Publicado: (2019)

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
por: Subbiah, Vivek, et al.
Publicado: (2014)

Rectal stromal tumor with an exceptional liver and bone metastatic locations
por: Wejih, Dougaz Mohamed, et al.
Publicado: (2019)

Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report
por: Takeuchi, Nobumichi, et al.
Publicado: (2019)

Regorafenib-Induced Radiation Recall Presenting as Acute Blood Loss Anemia With Rectal Bleeding and Severe Proctitis
por: Urella, Madhulika, et al.
Publicado: (2023)

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
por: Pairawan, Seyed, et al.
Publicado: (2022)

Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study
por: Archwamety, Anita, et al.
Publicado: (2022)

Cost–Utility and Budget Impact Analyses of Oral Chemotherapy for Stage III Colorectal Cancer: Real-World Evidence after Policy Implementation in Thailand
por: Phisalprapa, Pochamana, et al.
Publicado: (2023)

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
por: Sarshekeh, Amir Mehrvarz, et al.
Publicado: (2017)

Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM
por: Ma, Jennifer, et al.
Publicado: (2016)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer
por: Korphaisarn, Krittiya, et al.
Publicado: (2019)

Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study
por: Korphaisarn, Krittiya, et al.
Publicado: (2021)

From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology
por: Rodriguez, Julieta E., et al.
Publicado: (2023)

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer
por: Kopetz, Scott, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0dolbu820fqnah5ihiev937dd2